03 Dec 2021
United Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2022
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
United Therapeutics (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today announced that the...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 3, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients...
01 Nov 2021
United Therapeutics Corporation To Present At The Credit Suisse 30th Annual Healthcare Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 1, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer of United...
Amendment expands program from a singular focus on the bioprinting of human lung scaffolds to the development and demonstration of two additional human organs
Amendment will become effective...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2021 financial results before the...
Tyvaso DPI™ BREEZE pharmacokinetic data demonstrate similar exposure and lower variability for Tyvaso DPI compared with Tyvaso®Ten abstracts covering Tyvaso (treprostinil) Inhalation Solution, Orenitram® (treprostinil)...
18 Oct 2021
United Therapeutics Provides an Update on the Progress of the Tyvaso DPI™ New Drug Application
Draft label contains both PAH and PH-ILD indications; no contraindications and no boxed warning
Complete response cites an open inspection issue at a third-party analytical testing facility; no other deficiencies...
A total of 10 abstracts reinforce United Therapeutics' commitment to advancing research in pulmonary hypertension
Additional subgroup analyses evaluate data from the Tyvaso® INCREASE study in PH-ILD
Additional new...
30 Sep 2021
United Therapeutics Converts to a Public Benefit Corporation Following Shareholder Approval
Conversion officially aligns corporate charter with longstanding commitment to improve the lives of patients while creating sustainable shareholder value in a responsible manner
SILVER SPRING, Md. and RESEARCH TRIANGLE...
Report available at corporateresponsibility.unither.com
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 10, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced the release...
In subjects with PAH, transition from Tyvaso® to Tyvaso DPI™ demonstrated safety and tolerance with significant improvements in six-minute walk distance, device preference and satisfaction, and patient reported...
- Neuroblastoma is the most common cancer in infants less than one year old and the third-most common pediatric cancer in children less than 15 years old, accounting for 15 percent of childhood cancer deaths...